Mechanical thrombectomy with a novel device: initial clinical experience with the ANA thrombectomy device

Area of Science:

• Neurology
• Interventional Neuroradiology
• Biomedical Engineering

Background:

• The ANA™ (Anaconda Biomed) thrombectomy system is a novel device for stroke treatment.
• It features a self-expanding funnel to minimize clot fragmentation and facilitate clot removal.

Purpose of the Study:

• To investigate the safety and efficacy of the ANA™ thrombectomy system in a first-in-man study.
• To evaluate the device's performance in achieving reperfusion and clinical outcomes.

Main Methods:

• A prospective study of 35 consecutive patients treated with ANA™ as a first-line therapy.
• Outcome measures included reperfusion scores (mTICI), symptomatic intracerebral hemorrhage (sICH), NIHSS, and modified Rankin Scale (mRS).

Main Results:

• High rates of successful reperfusion (mTICI 2b-3) were achieved in 91.4% of patients within 3 passes.
• Complete recanalization (mTICI 2c-3) occurred in 65.7% of patients, with a first-pass rate of 42.9%.
• The device demonstrated a good safety profile with no device-related serious adverse events and a low sICH rate (5.7%).

Conclusions:

• The ANA™ device shows high complete recanalization rates and a favorable safety profile in initial clinical use.
• The system achieved promising 90-day clinical outcomes, with 60% of patients achieving an mRS of 0-2.